Neuroscience-focused clinical stage company Neurovance reported positive results from the Phase IIA pilot study of its non-stimulant drug for ADHD, EB-1020 SR, in adult male patients with all ADHD subtypes.
from Content Keyword RSS http://ift.tt/1mSnCou http://ift.tt/eA8V8J
Advertisements